BALCHEM CORP Q3 FY2026 earnings call

Financial Performance:

• Delivered record consolidated revenue of $291 million, an 8.6% increase year-over-year.
• Achieved record adjusted EBITDA of $80 million (up 12.4%) with a margin of 27.6%.
• Reported record GAAP net income of $47 million ($1.46 diluted EPS) and adjusted net income of $50 million ($1.57 diluted EPS).
• Generated strong cash flows, with $70 million from operations and $58 million in free cash flow.

Operational Highlights:

• Marked the 29th consecutive quarter of year-over-year growth in adjusted EBITDA.
• Human Nutrition and Health grew due to increased demand for specialty nutrients and 'better-for-you' food trends.
• Animal Nutrition and Health benefited from higher adoption of encapsulated rumen-protected nutrients in dairy and pricing actions in U.S. monogastric markets.
• Specialty Products saw steady growth driven by demand for performance gases and services.

Strategic Science & Marketing:

• Published new clinical data supporting Vitacoline (choline) for adult cognitive health and Alzheimer's risk mitigation (MD Anderson study).
• Published DANCODE trial results in Circulation supporting Vitamin K2 (K2 Vital Delta) for cardiovascular health and coronary artery calcification reduction.
• Management plans to intensify marketing efforts to build consumer awareness around these new scientific findings.

Capital Allocation:

• Repurchased approximately $28 million of common stock.
• Reduced net borrowings by $28 million, resulting in a net leverage ratio of 0.2x.
• Utilizing expanded $650 million credit facility for future innovation and potential acquisitions.

Human Nutrition and Health: Sales of $188 million (up 8.1% YoY), representing approximately 64.6% of total revenue. Operating earnings were a record $46 million (up 11.8%). Animal Nutrition and Health: Sales of $63 million (up 11.7%), representing approximately 21.6% of total revenue. Operating earnings were $6.8 million (up 82.8%). Specialty Products: Sales of $37 million (up 4.5%), representing approximately 12.7% of total revenue.

• No specific quantitative full-year or fourth-quarter financial guidance was provided during the call.
• Management noted that the fourth quarter is historically sequentially lower than the third quarter due to seasonality.
• Expressed confidence in delivering healthy year-over-year growth in Q4, consistent with the trajectory seen throughout the year.

• Inflationary pressures on raw material costs; while passed through to customers, this creates timing delays and slight margin dilution.
• Geopolitical instability and supply chain disruptions, leading to deliberate increases in safety stock inventory levels.
• Trade practices involving circumvention of anti-dumping duties in Europe and ongoing filings in the U.S. for animal nutrition products.
• High oil prices negatively impact margins via transportation, logistics, and petrochemical-derived raw material costs.

Q: Analyst asked about the sustainability of favorable mix benefits driving margins and how inflation impacts them. / A: CFO explained that favorable mix is structural: Human Nutrition’s high-margin nutrition segment grows faster than food ingredients, and Animal Nutrition’s high-margin ruminant business outpaces monogastric. Regarding inflation, they pass cost increases dollar-for-dollar to customers, resulting in a near break-even impact on gross margin percentage YTD, though timing lags exist. The beneficial portfolio mix helps offset the slight margin dilution from flat pass-throughs.

Q: Analyst asked for details on the next steps for the newly published Alzheimer’s and cardiovascular trials. / A: CEO clarified these are pilot/study additions to their broader science library. The Choline study targets adult cognition in ApoE4 carriers, paving the way for larger studies. The K2 Vital Delta study provides clinical evidence for cardiovascular benefits beyond bone health. Next steps involve aggressive marketing to create awareness among customers and consumers, leveraging the science to differentiate branded ingredients.

Q: Analyst inquired about drivers behind significant operating earnings growth in Animal Nutrition and the rise in inventory to $177 million. / A: CFO attributed A&H growth to penetration of encapsulated nutrients in dairy globally and regained volumes/pricing in European monogastrics due to anti-dumping duties. For inventory, four factors drove the increase: inflationary input costs, organic growth requiring more stock, deliberate safety stock buildup due to geopolitical risks, and pre-launch inventory for new product rollouts like next-gen methionine.

Q: Analyst asked about future clinical directions (sleep, athletic recovery, beauty) and potential partnerships in aesthetics or sports. / A: CEO confirmed ongoing investment in science for muscle recovery, sleep (magnesium), and 'beauty from within' (hair/skin/nails). They are actively exploring partnerships with cosmetic/aesthetic companies. Additionally, following successful NFL and Bayern Munich deals, they plan to announce another international sports partnership within the next month.